{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:02:43Z","timestamp":1792134163305,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116119","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T03:09:20Z","timestamp":1763608160000},"page":"116119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management"],"prefix":"10.1016","volume":"232","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6971-3424","authenticated-orcid":false,"given":"Baptiste","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Grosnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4502-0058","authenticated-orcid":false,"given":"Thomas","family":"Samaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-7464","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie H.","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-5162","authenticated-orcid":false,"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AndreThierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116119_bib1","article-title":"The prevalence and prognosis of microsatellite instability-high\/mismatch repair-deficient colorectal adenocarcinomas in the United States","volume":"7","author":"Gutierrez","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","article-title":"Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome","volume":"37","author":"Innocenti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib4","first-page":"5849","article-title":"Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history","volume":"53","author":"Lothe","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116119_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231170473","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: therapeutic advances and questions","volume":"16","author":"Cervantes","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib6","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib7","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116119_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib9","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116119_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116119_bib11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of primary resistance to immunecheckpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2020.11.009","article-title":"Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"144","author":"Colle","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116119_bib13","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib14","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1158\/2767-9764.CRC-23-0340","article-title":"Sustained disease control in immune checkpoint blockade responders with microsatellite instability-high colorectal cancer after treatment termination","volume":"3","author":"Simmons","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ejca.2025.116119_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116119_bib16","doi-asserted-by":"crossref","unstructured":"Higbie V.S., Shah P., Bent A. et al. Natural history and patterns of progression for dMMR\/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. Presentation at the ASCO Gastrointestinal Cancers Symposium 2024; Abstrac 145, J Clin Oncol 2024 42, 145-145. Available from: \u3008https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.3_suppl.145\u3009 [Accessed 15 July 2025].","DOI":"10.1200\/JCO.2024.42.3_suppl.145"},{"key":"10.1016\/j.ejca.2025.116119_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/cancers14020406","article-title":"Treatments after immune checkpoint inhibitors in patients with dMMR\/MSI metastatic colorectal cancer","volume":"14","author":"Bui","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116119_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","article-title":"Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability","volume":"34","author":"Ratovomanana","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib19","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-22-3964","article-title":"Transcriptomic signatures of MSI-high metastatic colorectal cancer predict efficacy of immune checkpoint inhibitors","volume":"29","author":"Gallois","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116119_bib20","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2217\/fon-2022-1105","article-title":"KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H\/dMMR metastatic colorectal cancer","volume":"19","author":"Andr\u00e9","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC","volume":"20","author":"Elez","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.116119_bib22","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1158\/2159-8290.CD-24-0771","article-title":"WRN Helicase: is there more to MSI-H than immunotherapy?","volume":"14","author":"Wainberg","year":"2024","journal-title":"Cancer Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:59:52Z","timestamp":1773827992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"alternative-id":["S0959804925010056"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116119","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116119"}}